Brokerages Expect Kezar Life Sciences, Inc. (NASDAQ:KZR) Will Post Earnings of -$0.31 Per Share

Equities analysts expect Kezar Life Sciences, Inc. (NASDAQ:KZRGet Rating) to report earnings per share (EPS) of ($0.31) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Kezar Life Sciences’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.28). Kezar Life Sciences reported earnings per share of ($0.25) in the same quarter last year, which would indicate a negative year-over-year growth rate of 24%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Kezar Life Sciences will report full year earnings of ($1.22) per share for the current financial year, with EPS estimates ranging from ($1.43) to ($1.07). For the next fiscal year, analysts forecast that the company will post earnings of ($1.23) per share, with EPS estimates ranging from ($1.45) to ($0.99). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Kezar Life Sciences.

Kezar Life Sciences (NASDAQ:KZRGet Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02.

KZR has been the topic of a number of research reports. Wells Fargo & Company cut their target price on shares of Kezar Life Sciences from $19.00 to $14.00 in a research note on Wednesday, May 4th. Zacks Investment Research lowered shares of Kezar Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, March 23rd. Finally, HC Wainwright lifted their target price on shares of Kezar Life Sciences from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, March 18th.

In other Kezar Life Sciences news, Director Franklin M. Berger bought 60,000 shares of Kezar Life Sciences stock in a transaction on Friday, March 18th. The stock was acquired at an average cost of $16.74 per share, with a total value of $1,004,400.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Franklin M. Berger bought 20,000 shares of Kezar Life Sciences stock in a transaction on Monday, March 21st. The shares were acquired at an average cost of $14.77 per share, with a total value of $295,400.00. The disclosure for this purchase can be found here. 7.70% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the business. Dorsey Wright & Associates bought a new position in shares of Kezar Life Sciences in the first quarter worth approximately $60,000. Royal Bank of Canada boosted its position in shares of Kezar Life Sciences by 68.6% in the third quarter. Royal Bank of Canada now owns 3,951 shares of the company’s stock worth $34,000 after purchasing an additional 1,608 shares during the period. Metropolitan Life Insurance Co NY bought a new position in shares of Kezar Life Sciences in the first quarter worth approximately $89,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Kezar Life Sciences in the fourth quarter worth approximately $93,000. Finally, Citigroup Inc. boosted its position in shares of Kezar Life Sciences by 35.5% during the third quarter. Citigroup Inc. now owns 6,323 shares of the company’s stock worth $55,000 after acquiring an additional 1,658 shares during the last quarter. 71.03% of the stock is owned by institutional investors and hedge funds.

Shares of Kezar Life Sciences stock traded up $0.23 during trading on Friday, hitting $5.75. 1,114,948 shares of the company’s stock traded hands, compared to its average volume of 1,202,364. The firm’s fifty day moving average price is $13.66 and its 200 day moving average price is $13.33. Kezar Life Sciences has a twelve month low of $4.61 and a twelve month high of $18.55. The company has a market cap of $326.08 million, a PE ratio of -5.53 and a beta of 0.49. The company has a debt-to-equity ratio of 0.05, a current ratio of 25.77 and a quick ratio of 25.77.

About Kezar Life Sciences (Get Rating)

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.

Further Reading

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.